🇺🇸 estrogen replacement therapy in United States

31 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Breast Cancer — 10 reports (32.26%)
  2. Breast Cancer Metastatic — 3 reports (9.68%)
  3. Condition Aggravated — 3 reports (9.68%)
  4. Drug Ineffective — 3 reports (9.68%)
  5. Angioneurotic Oedema — 2 reports (6.45%)
  6. Areflexia — 2 reports (6.45%)
  7. Arterial Spasm — 2 reports (6.45%)
  8. Brain Compression — 2 reports (6.45%)
  9. Breast Cancer Female — 2 reports (6.45%)
  10. Coma — 2 reports (6.45%)

Source database →

estrogen replacement therapy in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is estrogen replacement therapy approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for estrogen replacement therapy in United States?

National Heart, Lung, and Blood Institute (NHLBI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.